Large Cap / Mid Cap / Small Cap / Mutual Funds / Healthcare Equipment & Services / Pharmaceuticals, Biotechnology & Life Sciences

Health Care Stocks Poised for a Recovery

 

Want to know what George Putnam is recommending to readers of his Turnaround Letter? The articles previewed below offer you a sneak peak of the quality content and sound investment guidance you can trust. To view his most recent recommendations click here.

 

 

Health Care Stocks Poised for a Recovery

Many healthcare stocks have been on a rollercoaster ride over the last few years, buffeted by both positive and negative forces.  Among the positive forces are long-term demographic trends and advancements in medical technology.  Some of the most negative forces emanate from Washington, including the complexities of ObamaCare and the possibility of cuts to Medicare and Medicaid.

The stocks named in the subscriber-restricted article represent a diverse group of companies in the healthcare area.  Most of them have been riding the rollercoaster downwards for a while, but all of them have the potential to bottom out and begin to climb again in the coming months.

George Putnam's March 2013 Turnaround Letter article hand picks ten diverse healthcare stocks with potential to bottom out and—most importantly—begin improving stock performance in the coming months.

 

 

Read your free preview of The Turnaround Letter's most recent recommendations now!

 

 


 

 

 

 


 

 

Identify & Profit from Distressed Investing

Free Report: Turnaround Investing Mistakes

Turnaround Investing Blog

Turnaround Investing Blog

Turnaround Investing Philosophy: 32 Years Later, Some Things Never Change

Recently I was asked how my investing perspective changed over the 32 years of publishing The Turnaround Letter. It's a fascinating question because change is constant, and often beneficial (although that's not a given) in the business world. If change is the norm, can investing principles stay constant? I firmly believe that they can. Read More.

EV/EBITDA: What Is It & Why Are We Using It More?

In reading recent editions of The Turnaround Letter, you have probably noticed that we are increasingly using EV/EBITDA as a valuation measure, rather than the better-known price/earnings multiple.  We thought it might be useful to describe this measure and why we like it.

Read More.

Turnaround Letter Stock Pick Named Top Performer of 2017

 

stock market advicex

 

What Last Year's Top Stock Pickers Are Buying in 2018

 

This Forbes write-up follows up on the recent Top Stock Tips report--naming The Turnaround Letter's Crocs recommendation the top performer of 2017: With 90% gains, CROX beat out 100 other investment ideas included in the report; and the stock continues to have value investing appeal, according to Putnam.

 

George notes, "We see additional upside for the stock in 2018 as management's efforts continue to bear fruit, though the gains will likely be more muted than we saw in 2017."